Niagen Bioscience (NASDAQ: NAGE) has filed to offer up to $50,000,000 in common stock through a sales agreement dated June 26, 2026, with Canaccord Genuity LLC and Roth Capital Partners, LLC acting as sales agents.

Under the terms of the agreement, the company may sell shares of common stock with a par value of $0.001 per share from time to time through or to the agents, who may act as either agents or principals in the transactions.